Aspire Biopharma Holdings Inc. has completed private placements with certain investors under a Securities Purchase Agreement, selling notes with an aggregate principal amount of $9,687,500 for a total subscription price of $7,750,000. The first tranche of $4,709,677 was funded on August 19, 2025, and a second tranche of $1,000,000 was funded on September 22, 2025. The document does not specify the number of shares issued or the names of the investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-015773), on September 26, 2025, and is solely responsible for the information contained therein.